SkinBioTherapeutics PLC

This will put you to sleep

By Elric Langton & Alex Langton | 28 May 2025

Mike, Alex, and Elric are financially interested in SkinBioTherapeutics and OptiBiotix Health.

In this editorial, we take a closer look at Zenakine™—not merely as a breakthrough in skincare, but as a potential pivot point in the rapidly expanding sleep and wellness economy. While initially conceived as a neurocosmetic active for skin health and emotional wellbeing, Zenakine™’s scientifically validated impact on sleep quality has sparked unexpected interest from sectors well beyond traditional beauty. From pillow mists to aromatherapy and even textile applications, this multifunctional ingredient is now opening commercial doors that neither SkinBioTherapeutics nor its partner Croda had fully anticipated, as candidly noted by CEO Stuart Ashman. With consumer obsession around sleep intensifying—and the boundaries between wellness, beauty, and biotech increasingly blurred—Zenakine™ presents investors with an opportunity that extends far beyond the face cream aisle.